Psyence Biomedical Receives Nasdaq Delisting Determination; Company Has Not Regained Compliance
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical has received a delisting determination from Nasdaq due to non-compliance. The company has not regained compliance with Nasdaq's listing requirements.
September 13, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Psyence Biomedical has been issued a delisting determination by Nasdaq as it has not regained compliance with listing requirements.
The delisting determination from Nasdaq is a significant negative event for Psyence Biomedical, indicating potential financial instability or operational issues. This is likely to lead to a decrease in investor confidence and a drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100